Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to control Hard-to-Treat myeloma

NCT ID NCT05338775

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage study tests whether combining two types of immune-boosting drugs (bispecific antibodies and a checkpoint inhibitor) is safe for people with multiple myeloma that has come back or stopped responding to treatment. About 74 participants will receive either talquetamab or teclistamab together with a PD-1 inhibitor. The main goal is to find safe doses and check for side effects, not to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

  • CHU Poitiers - Hopital la Miletrie

    Poitiers, 86021, France

  • CHU de Montpellier Hopital Saint Eloi

    Montpellier, 34295, France

  • CHU de Nantes hotel Dieu

    Nantes, 44093, France

  • Clinica Univ. de Navarra

    Pamplona, 31008, Spain

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Hosp Clinico Univ de Salamanca

    Salamanca, 37007, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040, Spain

  • Hosp. Univ. Germans Trias I Pujol

    Badalona, 08916, Spain

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Institut Universitaire du Cancer Toulouse Oncopole

    Toulouse, 31059, France

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • The Blavatnik Family Chelsea Medical Center at Mount Sinai

    New York, New York, 10011, United States

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, 20246, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • Universitatsklinikum Carl Gustav Carus Dresden

    Dresden, 01307, Germany

  • Universitatsklinikum Wurzburg

    Würzburg, 97080, Germany

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.